## **Supplementary Online Content**

Boesen L, Nørgaard N, Løgager V, et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the Biparametric MRI for Detection of Prostate Cancer (BIDOC) study. *JAMA Netw Open.* 2018;1(1):e180219. doi:10.1001/jamanetworkopen.2018.0219

eTable 1. Biparametric MRI Sequence Parameters

**eTable 2.** Patient Characteristics of Men (n = 8) With Low-Suspicion bpMRIs (PI<sub>mod</sub> 1-2)

eFigure 1. Comparison of bpMRI Suspicion Scores to Cancer Significance

eFigure 2. Decision Curve Analysis

This supplementary material has been provided by the authors to give readers additional information about their work.

Sequence	TR	TE	NEX/Ave	FOV (mm)	Resolution/	Slices	Slice	Gap	Time
	(ms)	(ms)	rages		Voxel size (mm)	(n)	thickness	(mm)	(min:sec)
							(mm)		
Sagittal	3.3	1.65	2	AP 270	<u>ACQ:</u>	14	3	1	00:29
luxury scout				LR 55	$1.5 \times 1.5 \times 3$				
-				FH 270	Recon:				
					0.84  imes 0.84  imes 3				
T2W TSE	3,745	90	1	AP 180	ACQ:	30	3	0.5	8:52
Axial				LR 180	0.45  imes 0.45  imes 3				
				FH 104	Recon:				
					0.22  imes 0.22  imes 3				
Diffusion	9,983	71	2	AP 180	<u>ACQ:</u>	26	4	0	6:30
EPI b-value:				LR 180	2.1  imes 2.2  imes 4				
0, 100, 800,				FH 104	Recon:				
2,000					0.8 imes 0.8 imes 4				


eTable 1. Biparametric MRI Sequence Parameters

T2W = T2-weighted imaging; TSE = turbo spin echo; EPI = echo planar imaging; TR = repetition time; TE = echo time; FA = flip angle; ACQ = acquisition matrix; Recon = reconstruction; NEX = number of excitations/average signals; FOV = field of view; AP = anterior-posterior; LR = left-right; FH = foot-head

Patient ID	Time	Age (years)	PSA	cT <sub>DR</sub>	Prostate	PSA density	Standard	Gleaso	MCCL	BpMR
	MRI to		(ng/ml)	Е	volume	(ng/ml/cc)	PCa	n score		I PI <sub>mod</sub>
	bx (days)			stage	(ml)		positive	/ Grade		score
							cores	group		
							(num/10			
							)			
420	7	67	4.4	T1c	37	0.12	2	4+3/3	25	2
536	9	70	7.2	T2c	54	0.13	10	4+5 / 5	100	1
582	2	54	4.7	T1c	34	0.14	1	4+4 / 4	10	1
649	6	62	5.9	T1c	58	0.10	2	4+3/3	35	2
701	2	57	14	T1c	81	0.17	4	3+4 / 2	70	1
839	6	70	8.7	T1c	48	0.18	2	4+3/3	50	1
911	6	72	4.7	T2b	18	0.26	5	4+3/3	85	1
1013	2	66	5.4	Tx	88	0.06	1	4+4 / 4	15	1
Median	6 [6–6]	67 [67–70]	5.7 [5.7–		51 [51–	0.14 [0.14–			43 [43–	
[IQR]			7.6]		64]	0.17]			74]	

**eTable 2.** Patient Characteristics of Men (n = 8) With Low-Suspicion bpMRIs (PI<sub>mod</sub> 1-2)


 $PCa = prostate cancer; cT_{DRE} = tumor stage by digital rectal examination; MCCL = maximum cancer-core length; IQR = Inter quartile range; <math>PI_{mod} = modified$  prostate imaging reporting and data system score




eFigure 1. Comparison of bpMRI Suspicion Scores to Cancer Significance

PCa = prostate cancer; InsPCa = insignificant PCa; sPCa = significant PCa; bpMRI = biparametric MRI; PI<sub>mod</sub> = modified prostate imaging reporting and data system

Prostate cancer detection rates for all patients (N = 1020) based on combined (standard plus targeted) biopsy results and stratified by cancer significance (primary definition) within each bpMRI  $PI_{mod}$  score. All men underwent standard biopsies, but only those with bpMRI  $PI_{mod}$  3–5 also underwent targeted biopsies.





Decision curve showing net benefit for carrying out biopsies in men at risk of significant prostate cancer. The net benefit for carrying out standard biopsies in all men (standard approach) is lower for all threshold probabilities compared to using bpMRI as a triage test and perform combined biopsies restricted to men with suspicious bpMRI ( $PI_{mod}$  3–5). The dotted vertical line indicates a threshold of 5 % equivalent to perform biopsies in 20 men to find one additional sPCa.